Login
Evidence Feed
About
Conferences
New
Diagnostics
New
Top genes
New
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
HER-2 positive
i
Other names:
ERBB2, CD340, HER-2, HER2, NEU, NGL, V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
2064
Related biomarkers:
Expression
Mutation
CNA
Fusion
Others
‹
›
Associations
News
Twitter
Trials
Reset Filters
VERI cancer hierarchy
x
x
x
x
HER-2 positive
HER2 Positive Breast Cancer
HER-2 positive
HER2 Positive Breast Cancer
capecitabine
Sensitive: A2 - Guideline
NCCN - 1 week (New A2)
capecitabine
Sensitive
:
A2
NCCN - 1wk
capecitabine
Sensitive: A2 - Guideline
NCCN - 1 week
capecitabine
Sensitive
:
A2
NCCN - 1 week - (New A2)
HER-2 positive
Cholangiocarcinoma
HER-2 positive
Cholangiocarcinoma
BI 1810631
Sensitive: C3 – Early Trials
IASLC-TTLC 2023 - 1 week (New C3)
BI 1810631
Sensitive
:
C3
IASLC-TTLC 2023 - 1wk
BI 1810631
Sensitive: C3 – Early Trials
IASLC-TTLC 2023 - 1 week
BI 1810631
Sensitive
:
C3
IASLC-TTLC 2023 - 1 week - (New C3)
HER-2 positive
Esophageal Cancer
HER-2 positive
Esophageal Cancer
BI 1810631
Sensitive: C3 – Early Trials
IASLC-TTLC 2023 - 1 week (New C3)
BI 1810631
Sensitive
:
C3
IASLC-TTLC 2023 - 1wk
BI 1810631
Sensitive: C3 – Early Trials
IASLC-TTLC 2023 - 1 week
BI 1810631
Sensitive
:
C3
IASLC-TTLC 2023 - 1 week - (New C3)
HER-2 positive
HER2 Positive Breast Cancer
HER-2 positive
HER2 Positive Breast Cancer
dasatinib + lapatinib
Sensitive: D – Preclinical
PLoS One - 1 week (New D)
dasatinib + lapatinib
Sensitive
:
D
PLoS One - 1wk
dasatinib + lapatinib
Sensitive: D – Preclinical
PLoS One - 1 week
dasatinib + lapatinib
Sensitive
:
D
PLoS One - 1 week - (New D)
HER-2 positive
HER2 Positive Breast Cancer
HER-2 positive
HER2 Positive Breast Cancer
ado-trastuzumab emtansine
Sensitive: A1 - Approval
Breast - 3 weeks (New C3)
ado-trastuzumab emtansine
Sensitive
:
A1
Breast - 3wk
ado-trastuzumab emtansine
Sensitive: A1 - Approval
Breast - 3 weeks
ado-trastuzumab emtansine
Sensitive
:
A1
Breast - 3 weeks - (New C3)
HER-2 positive
Gastric Cancer
HER-2 positive
Gastric Cancer
pyrotinib + dalpiciclib
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 3 weeks (New C3)
pyrotinib + dalpiciclib
Sensitive
:
C2
ASCO-GI 2023 - 3wk
pyrotinib + dalpiciclib
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 3 weeks
pyrotinib + dalpiciclib
Sensitive
:
C2
ASCO-GI 2023 - 3 weeks - (New C3)
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
camrelizumab + pyrotinib
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 3 weeks (New C3)
camrelizumab + pyrotinib
Sensitive
:
C3
ASCO-GI 2023 - 3wk
camrelizumab + pyrotinib
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 3 weeks
camrelizumab + pyrotinib
Sensitive
:
C3
ASCO-GI 2023 - 3 weeks - (New C3)
HER-2 positive
Gastric Cancer
HER-2 positive
Gastric Cancer
camrelizumab + pyrotinib
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 3 weeks (New C3)
camrelizumab + pyrotinib
Sensitive
:
C3
ASCO-GI 2023 - 3wk
camrelizumab + pyrotinib
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 3 weeks
camrelizumab + pyrotinib
Sensitive
:
C3
ASCO-GI 2023 - 3 weeks - (New C3)
HER-2 positive
Gastric Cancer
HER-2 positive
Gastric Cancer
olaparib + durvalumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 3 weeks (New C3)
olaparib + durvalumab
Sensitive
:
C3
ASCO-GI 2023 - 3wk
olaparib + durvalumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 3 weeks
olaparib + durvalumab
Sensitive
:
C3
ASCO-GI 2023 - 3 weeks - (New C3)
HER-2 positive
Gastric Cancer
HER-2 positive
Gastric Cancer
paclitaxel + minnelide
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 3 weeks (New C3)
paclitaxel + minnelide
Sensitive
:
C3
ASCO-GI 2023 - 3wk
paclitaxel + minnelide
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 3 weeks
paclitaxel + minnelide
Sensitive
:
C3
ASCO-GI 2023 - 3 weeks - (New C3)
HER-2 positive
HER2 Positive Breast Cancer
HER-2 positive
HER2 Positive Breast Cancer
trastuzumab + tucatinib
Sensitive: A1 - Approval
trastuzumab + tucatinib
Sensitive
:
A1
trastuzumab + tucatinib
Sensitive: A1 - Approval
trastuzumab + tucatinib
Sensitive
:
A1
HER-2 positive
HER2 Positive Breast Cancer
HER-2 positive
HER2 Positive Breast Cancer
trastuzumab + pertuzumab
Sensitive: A1 - Approval
trastuzumab + pertuzumab
Sensitive
:
A1
trastuzumab + pertuzumab
Sensitive: A1 - Approval
trastuzumab + pertuzumab
Sensitive
:
A1
HER-2 positive
HER2 Positive Breast Cancer
HER-2 positive
HER2 Positive Breast Cancer
margetuximab
Sensitive: A1 - Approval
margetuximab
Sensitive
:
A1
margetuximab
Sensitive: A1 - Approval
margetuximab
Sensitive
:
A1
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
trastuzumab
Sensitive: A1 - Approval
trastuzumab
Sensitive
:
A1
trastuzumab
Sensitive: A1 - Approval
trastuzumab
Sensitive
:
A1
HER-2 positive
HER2 Positive Breast Cancer
HER-2 positive
HER2 Positive Breast Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive: A1 - Approval
fam-trastuzumab deruxtecan-nxki
Sensitive
:
A1
fam-trastuzumab deruxtecan-nxki
Sensitive: A1 - Approval
fam-trastuzumab deruxtecan-nxki
Sensitive
:
A1
HER-2 positive
Gastric Cancer
HER-2 positive
Gastric Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive: A1 - Approval
fam-trastuzumab deruxtecan-nxki
Sensitive
:
A1
fam-trastuzumab deruxtecan-nxki
Sensitive: A1 - Approval
fam-trastuzumab deruxtecan-nxki
Sensitive
:
A1
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
fam-trastuzumab deruxtecan-nxki
Sensitive: A1 - Approval
fam-trastuzumab deruxtecan-nxki
Sensitive
:
A1
fam-trastuzumab deruxtecan-nxki
Sensitive: A1 - Approval
fam-trastuzumab deruxtecan-nxki
Sensitive
:
A1
HER-2 positive
HER2 Positive Breast Cancer
HER-2 positive
HER2 Positive Breast Cancer
trastuzumab
Sensitive: A1 - Approval
trastuzumab
Sensitive
:
A1
trastuzumab
Sensitive: A1 - Approval
trastuzumab
Sensitive
:
A1
HER-2 positive
Gastric Cancer
HER-2 positive
Gastric Cancer
pembrolizumab + trastuzumab
Sensitive: A1 - Approval
pembrolizumab + trastuzumab
Sensitive
:
A1
pembrolizumab + trastuzumab
Sensitive: A1 - Approval
pembrolizumab + trastuzumab
Sensitive
:
A1
HER-2 positive
HER2 Positive Breast Cancer
HER-2 positive
HER2 Positive Breast Cancer
pertuzumab/trastuzumab/hyaluronidase-zzxf
Sensitive: A1 - Approval
pertuzumab / trastuzumab / hyaluronidase-zzxf
Sensitive
:
A1
pertuzumab/trastuzumab/hyaluronidase-zzxf
Sensitive: A1 - Approval
pertuzumab / trastuzumab / hyaluronidase-zzxf
Sensitive
:
A1
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
trastuzumab-qyyp
Sensitive: A1 - Approval
trastuzumab-qyyp
Sensitive
:
A1
trastuzumab-qyyp
Sensitive: A1 - Approval
trastuzumab-qyyp
Sensitive
:
A1
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
trastuzumab-dttb
Sensitive: A1 - Approval
trastuzumab-dttb
Sensitive
:
A1
trastuzumab-dttb
Sensitive: A1 - Approval
trastuzumab-dttb
Sensitive
:
A1
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
trastuzumab-dkst
Sensitive: A1 - Approval
trastuzumab-dkst
Sensitive
:
A1
trastuzumab-dkst
Sensitive: A1 - Approval
trastuzumab-dkst
Sensitive
:
A1
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
trastuzumab-anns
Sensitive: A1 - Approval
trastuzumab-anns
Sensitive
:
A1
trastuzumab-anns
Sensitive: A1 - Approval
trastuzumab-anns
Sensitive
:
A1
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
trastuzumab-pkrb
Sensitive: A1 - Approval
trastuzumab-pkrb
Sensitive
:
A1
trastuzumab-pkrb
Sensitive: A1 - Approval
trastuzumab-pkrb
Sensitive
:
A1
HER-2 positive
HER2 Positive Breast Cancer
HER-2 positive
HER2 Positive Breast Cancer
neratinib
Sensitive: A1 - Approval
neratinib
Sensitive
:
A1
neratinib
Sensitive: A1 - Approval
neratinib
Sensitive
:
A1
HER-2 positive
Salivary Gland Cancer
HER-2 positive
Salivary Gland Cancer
trastuzumab
Sensitive: A1 - Approval
trastuzumab
Sensitive
:
A1
trastuzumab
Sensitive: A1 - Approval
trastuzumab
Sensitive
:
A1
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
Zercepac (trastuzumab biosimilar)
Sensitive: A1 - Approval
Zercepac (trastuzumab biosimilar)
Sensitive
:
A1
Zercepac (trastuzumab biosimilar)
Sensitive: A1 - Approval
Zercepac (trastuzumab biosimilar)
Sensitive
:
A1
HER-2 positive
HER2 Positive Breast Cancer
HER-2 positive
HER2 Positive Breast Cancer
Zercepac (trastuzumab biosimilar)
Sensitive: A1 - Approval
Zercepac (trastuzumab biosimilar)
Sensitive
:
A1
Zercepac (trastuzumab biosimilar)
Sensitive: A1 - Approval
Zercepac (trastuzumab biosimilar)
Sensitive
:
A1
HER-2 positive
Gastric Cancer
HER-2 positive
Gastric Cancer
Zercepac (trastuzumab biosimilar)
Sensitive: A1 - Approval
Zercepac (trastuzumab biosimilar)
Sensitive
:
A1
Zercepac (trastuzumab biosimilar)
Sensitive: A1 - Approval
Zercepac (trastuzumab biosimilar)
Sensitive
:
A1
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
pembrolizumab + trastuzumab
Sensitive: A1 - Approval
pembrolizumab + trastuzumab
Sensitive
:
A1
pembrolizumab + trastuzumab
Sensitive: A1 - Approval
pembrolizumab + trastuzumab
Sensitive
:
A1
HER-2 positive
Colorectal Cancer
HER-2 positive
Colorectal Cancer
trastuzumab + pertuzumab
Sensitive: A1 - Approval
trastuzumab + pertuzumab
Sensitive
:
A1
trastuzumab + pertuzumab
Sensitive: A1 - Approval
trastuzumab + pertuzumab
Sensitive
:
A1
HER-2 positive
Gastric Cancer
HER-2 positive
Gastric Cancer
trastuzumab
Sensitive: A2 - Guideline
trastuzumab
Sensitive
:
A2
trastuzumab
Sensitive: A2 - Guideline
trastuzumab
Sensitive
:
A2
HER-2 positive
HER2 Positive Breast Cancer
HER-2 positive
HER2 Positive Breast Cancer
THP
Sensitive: A2 - Guideline
THP
Sensitive
:
A2
THP
Sensitive: A2 - Guideline
THP
Sensitive
:
A2
HER-2 positive
HER2 Positive Breast Cancer
HER-2 positive
HER2 Positive Breast Cancer
TCHP
Sensitive: A2 - Guideline
TCHP
Sensitive
:
A2
TCHP
Sensitive: A2 - Guideline
TCHP
Sensitive
:
A2
HER-2 positive
HER2 Positive Breast Cancer
HER-2 positive
HER2 Positive Breast Cancer
trastuzumab + abemaciclib
Sensitive: A2 - Guideline
trastuzumab + abemaciclib
Sensitive
:
A2
trastuzumab + abemaciclib
Sensitive: A2 - Guideline
trastuzumab + abemaciclib
Sensitive
:
A2
HER-2 positive
HER2 Positive Breast Cancer
HER-2 positive
HER2 Positive Breast Cancer
TCH
Sensitive: A2 - Guideline
TCH
Sensitive
:
A2
TCH
Sensitive: A2 - Guideline
TCH
Sensitive
:
A2
HER-2 positive
HER2 Positive Breast Cancer
HER-2 positive
HER2 Positive Breast Cancer
trastuzumab + lapatinib
Sensitive: A2 - Guideline
trastuzumab + lapatinib
Sensitive
:
A2
trastuzumab + lapatinib
Sensitive: A2 - Guideline
trastuzumab + lapatinib
Sensitive
:
A2
HER-2 positive
Gastroesophageal Cancer
HER-2 positive
Gastroesophageal Cancer
trastuzumab
Sensitive: A2 - Guideline
trastuzumab
Sensitive
:
A2
trastuzumab
Sensitive: A2 - Guideline
trastuzumab
Sensitive
:
A2
HER-2 positive
Esophageal Adenocarcinoma
HER-2 positive
Esophageal Adenocarcinoma
trastuzumab
Sensitive: A2 - Guideline
trastuzumab
Sensitive
:
A2
trastuzumab
Sensitive: A2 - Guideline
trastuzumab
Sensitive
:
A2
HER-2 positive
Endometrial Cancer
HER-2 positive
Endometrial Cancer
trastuzumab
Sensitive: A2 - Guideline
trastuzumab
Sensitive
:
A2
trastuzumab
Sensitive: A2 - Guideline
trastuzumab
Sensitive
:
A2
HER-2 positive
HER2 Positive Breast Cancer
HER-2 positive
HER2 Positive Breast Cancer
pertuzumab
Sensitive: A2 - Guideline
pertuzumab
Sensitive
:
A2
pertuzumab
Sensitive: A2 - Guideline
pertuzumab
Sensitive
:
A2
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login